Diagnosis and management of Hereditary Angioedema

Journal of the American Osteopathic Association

Volumn 111, Issue 1, 2011, Pages 28-36

  Johnston, Douglas T ^a  

^a Allergy Partners of the Upstate   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; DANAZOL; SERPING1 PROTEIN, HUMAN;

ADULT; ALGORITHM; ANGIONEUROTIC EDEMA; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; FEMALE; GENETICS; HUMAN; MALE; REVIEW; RISK FACTOR; SECRETION;

ADULT; ALGORITHMS; ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C4; DANAZOL; DIAGNOSIS, DIFFERENTIAL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MALE; RISK FACTORS; YOUNG ADULT;

EID: 79953187961     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States [review]. Immunol Allergy Clin North Am. 2006;26(4):653-668.
2. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. Sep 2004;114(3 suppl):S51-S131.
3. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417-2429.
4. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379-394.
5. Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current stateof-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(1 suppl 2):S30-S40.
6. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267-274.
7. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
8. Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484.e1-4.
9. Moore GP, Hurley WT, Pace SA. Hereditary angioedema. Ann Emerg Med. 1988;17(10):1082-1086.
10. Santos CB, Lunn ML, Craig TJ. Shortcomings in the diagnosis of hereditary angioedema: are we adequately screening family members of affected patients? [abstract P50]. Ann Allergy Asthma Immunol. 2009;102:A38.
11. Zuraw BL. Hereditary angiodema: a current state-of-the-art review, IV: short-and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol. 2008;100(1 suppl 2):S13-S18.
12. Wilson D, Rentz A, Zuraw B, et al. Economic costs associated with acute and chronic management of hereditary angioedema [abstract]. Ann Allergy Asthma Immunol. 2009;102(suppl 1):A92. Abstract P250.
13. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84(5):580-593.
14. Castaldo AJ, Vernon MK, Lumry WR, et al. Humanistic burden of hereditary angioedema [abstract]. Ann Allergy Asthma Immunol. 2009;102:A92. Abstract P249.
15. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71(4):206-215.
16. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc. 2003;134(8):1088-1094.
17. Davis AE III. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am. 2006;26(4):633-651.
18. Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ. 2006;175(9):1065-1070.
19. Weis M. Clinical review of hereditary angioedema: diagnosis and management. Postgrad Med. 2009;121(6):113-120.
20. Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am. 2006;26(4):669-690.
21. Grigoriadou S, Longhurst HJ. Clinical immunology review series: an approach to the patient with angio-oedema. Clin Exp Immunol. 2009;155(3):367-377.
22. Frigas E, Park M. Idiopathic recurrent angioedema. Immunol Allergy Clin North Am. 2006;26(4):739-751.
23. Kaplan A. Angioedema. World Allergy Organ J. 2008:1(6):103-113.
24. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema [review]. Immunol Allergy Clin North Am. 2006;26(4):725-737.
25. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004;164(8):910-913.
26. Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, O'Connell EJ, Kohler PF. Episodic angioedema associated with eosinophilia. N Engl J Med. 1984;310(25):1621-1626.
27. Cinryze [package insert]. New York, NY: Lev Pharmaceuticals Inc; 2008.
28. Danazol [package insert]. Philadelphia, PA: Lannett Co Inc; 2007.
29. Epstein TG, Bernstein JA. Current and emerging management options for hereditary angioedema in the US. Drugs. 2008;68(18):2561-2573.
30. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153-161.
31. Leimgruber A, Jaques WA, Spaeth PJ. Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy. Int Arch Allergy Immunol. 1993;101(1):107-112.
32. Berinert [package insert]. Kankakee, IL: CSL Behring LLC; 2009.
33. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808.
34. Kalbitor [package insert]. Cambridge, MA: Dyax Corp; 2009.
35. European Medicines Agency. CHMP Assessment Report for Firazyr. London, England: European Medicines Agency; 2008. EMEA/350457/2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000899/WC500022970.pdf. Accessed December 1, 2010.
36. Deeks ED. Icatibant. Drugs. 2010;70(1):73-81.